The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 1

Characteristics of studies included in this meta-analysis.

Study and group	Median; age	Induction; regimen	Maintenance; regimen	Number of; enrolled	Male; (%)	Stage of; disease
J. Patel (2013) [11]
Intervention arm	65	(Pem)500mg/m2,; (C)AUC6, (Bev)15mg/kg; four 21-day cycles	(Pem)500 mg/m2,; (Bev) 15 mg/kg	472	251(53.2%)	IIIBIV
Control arm	65	(Pac) 200 mg/m2,; (C)AUC6, (Bev) 15mg/kg; four 21-day cycles	(Bev) 15 mg/kg	467	249(53.3%)
F. Barlesi (2013) [12]
Intervention arm	60	(Pem)500mg/m2; (Bev)7.5 mg/kg, (Cis)75mg/m2; four 21-day cycles	(Pem)500mg/m2; (Bev)7.5 mg/kg,	128	72(57.6%)	IIIBIV
Control arm	60	(Pem)500mg/m2; (Bev)7.5 mg/kg, (Cis)75mg/m2; four 21-day cycles	(Bev)7.5 mg/kg	125	68(56.7%)
M. Karayama (2016) [13]
Intervention arm	65	(Pem)500mg/m2,; (C)AUC6, (Bev)15mg/kg; four 21-day cycles	(Pem)500 mg/m2,; (Bev) 15 mg/kg	55	35(63.6%)	IIIBIV
Control arm	66	(Pem)500mg/m2,; (C)AUC6, (Bev)15mg/kg; four 21-day cycles	(Pem)500 mg/m2	55	39(70.9%)

Pem, pemetrexed; Bev, bevacizumab; C, carboplatin; Pac, paclitaxel; Cis, cisplatin; AUC, area under the serum concentration-time curve